First fill-finish service from iBio aims to accelerate movement to the clinic

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/filipjelic)
(Image: Getty/filipjelic)

Related tags: Biologics, Gmp, preclinical, Viral vector, Capacity utilization

To get biologics to market faster, iBio launches sterile fill-finish operations for preclinical and clinical biologic products.

iBio launched its first current good manufacturing practice (cGMP) sterile fill-finish capabilities. The services have been designed to move clients with preclinical and clinical stage programs for pharmaceutical products, such as monoclonal antibodies, viral vectors, and other biologics, into the clinic and onto the market faster.

The fill-finish operations from the plant-based biopharmaceutical contract development and manufacturing organization (CDMO) will be housed in its 135,000 square-foot facility in Bryan, Texas. The sterile liquid fill-finish capability will combine in-line labeling to enable the serialization of vials during filling.

iBio said the initial capacity will support between 100 to 2,500 vials runs but the company is already able to produce 15,000 vials per shift at a capacity of 5ml fill volume.  

Nicolas Taquet, VP of biopharmaceutical manufacturing at iBio, explained that the company has been preparing for this expansion and will deploy a strategy that uses pre-fabricated cleanroom pods which can readily scale operations and add capacity directly to the allocated space in the facility.

He added that the company plans on adding an additional M&O Perry filler within a pre-fabricated cleanroom pod to double its capacity.

Launching this service comes directly from the growing need for fill-finish capabilities for biologics, according to Taquet.

He said, “Our clients were asking for help given that many are facing long lead times and high costs for certain product types – like viral vectors – or for small runs like early stage clinical and orphan drug trials.”

“Debottlenecking fill-finish is complementary to iBio’s plant-based platform for protein expression and glycan engineering capability​. Now, we can fill for clients as well, and help them get to trials, and ultimately to market faster,”​ Taquet concluded.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars